TCR-enriched clonotype, acquisition method and use thereof
US12252526B2 · kind B2 · utility
0Cited by
0References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2021 |
| Grant date | Mar 18, 2025 |
| Priority date | — |
| Expiry date | Jul 8, 2043 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/68
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed are TCR-enriched clonotypes, and an acquisition method and use thereof. Amino acid sequences of the TCR-enriched clonotypes are: CAANRGSGYSTLTF (SEQ ID NO: 1)_CSARGERGEKLFF (SEQ ID NO: 2), CASSSGGSYIPTF (SEQ ID NO: 3)_CASSLAGGHETQYF (SEQ ID NO: 4), CAVNSYNTDKLIF (SEQ ID NO: 5)_CATSREEDNTYEQYF (SEQ ID NO: 6), CAVGGNEKLTF (SEQ ID NO: 7)_CASSQGTGRSSPLHF (SEQ ID NO: 8), or CAASAVGGAQKLVF (SEQ ID NO: 9)_CATSRGTLYGYTF (SEQ ID NO: 10), respectively. The TCR-enriched clonotypes can be used for vaccine development.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.